.jpg)
18.A Comparative Analysis of Acute Kidney Injury Incidence in Patients Treated with Vancomycin in Combination with Piperacillin-Tazobactam or Meropenem
Muhammad Haroon Ghous, Sikander Afzal amd Mahwish Arooj
ABSTRACT
Objective: The main objective of the study is to find the comparison of acute kidney injury incidence in patients treated with vancomycin, piperacillin-tazobactam, or meropenem.
Study Design: cross-sectional study
Place and Duration of Study: This study was conducted at the University of Lahore Teaching Hospital, Pakistan, from January 2018 to December 2022.
Materials and Methods: The study aimed to investigate the occurrence of acute kidney injury (AKI) in patients receiving treatment with either vancomycin or beta-lactam antibiotics, specifically piperacillin-tazobactam and meropenem.
Results: Data was collected from 350 patients of both genders. Among the participants, 150 patients received vancomycin, 120 patients received piperacillin-tazobactam, and 80 patients received meropenem for the treatment of bacterial infections. The mean age of the participants was 50 years, with a standard deviation of 12 years. The majority of patients were male (60%) and had no history of chronic kidney disease (82%). Regarding AKI occurrence, the results showed that 35 patients developed AKI during the course of antibiotic treatment. Among them, 15 patients were in the vancomycin group, 12 in the piperacillin-tazobactam group, and 8 in the meropenem group. The overall incidence of AKI in the study population was 10%.
Conclusion: It is concluded that the risk of AKI is similar in patients receiving vancomycin and beta-lactam antibiotics. Close monitoring and individualized antibiotic selection are essential to optimize patient outcomes and reduce the risk of renal complications. Age and comorbidities were not major risk factors for AKI in this cohort.
Key Words: AKI, Renal, Patients, Antibiotic, Nephrotoxic